REFERENCES
- Corman S H, Fedutes B A, Culley C M. Atomoxetine: The first nonstimulant for the management of attention deficit/hyperactivity disorder. Am J Health-Syst Pharm 2004; 61: 2391–2399
- Wolfe F, Smythe H A, Yunus M B, Bennett R M, Bombardier C, Goldenberg D L, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum 1990; 33: 160–172
- Max M B. Antidepressants as analgesics. Progress in Pain Research and Therapy Vol 1, H L Fields, J C Liebskind. IASP Press, Seattle 1994; 229–246
- Offenbaecher M, Ackenheil M. Current trends in neuropathic pain treatments with special reference to fibromyalgia. CNS Spectr 2005; 10: 285–297
- Gendreau R M, Thorn M D, Gendreau J F, Kranzler J D, Ribeiro S, Gracely H, Williams D A, Mease P J, McLean S A, Clauw D J. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005; 32: 1975–1985
- Arnold L M, Rosen A, Pritchett Y L, D'Souza D N, Goldstein D J, Iyengar S, Wernicke J F. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5–15
- Raskin J, Pritchett Y L, Wang F, D'Souza D N, Waninger A L, Iyengar S, Wernicke J F. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6: 346–356
- Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: A review of current literature. Harvard Rev. Psychiatry 200; 7: 257–277
- Stahl S M, Grady M M, Moret C, Briley M. SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 200; 10: 732–747
- Coluzzi F, Mattia C. Mechanism-based treatment in chronic neuropathic pain: The role of antidepressants. Curr Pharm Des 2005; 11: 2945–2960
- Bymaster F P, Katner J S, Nelson D L, Hemrick-Luecke K H, Threlkeld P G, Heiligenstein J H, Morin S M, Gehlert D R, Perry K W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699–711
- Vaishnavi S N, Nemeroff C B, Plott S J, Rao S G, Kranzler J, Owens M J. Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004; 55: 320–322
- Swanson C J, Perry K W, Koch-Krueger S, Katner J, Svensson K A, Bymaster F P. Effect of attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentration of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 2006; 50: 755–760
- Heil S H, Holmes H W, Bickel W K, Higgins S T, Badger G J, Laws H F, Faries D E. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002; 67: 149–156